MolMed S.p.A. | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
18,169.00
13,003.00
20,784.00
13,876.00
8,497.00
Depreciation, Depletion & Amortization
511.00
411.00
626.00
1,093.00
1,349.00
Other Funds
121.00
306.00
873.00
192.00
-
Funds from Operations
16,257.00
11,908.00
19,455.00
12,330.00
7,110.00
Changes in Working Capital
2,614.00
5,691.00
3,619.00
163.00
3,354.00
Net Operating Cash Flow
13,643.00
6,217.00
15,836.00
12,167.00
10,464.00
Capital Expenditures
1,004.00
4,734.00
6,152.00
1,955.00
1,957.00
Purchase/Sale of Investments
-
-
18,163.00
17,999.00
5,005.00
Net Investing Cash Flow
5,996.00
4,733.00
24,315.00
16,044.00
6,962.00
Issuance/Reduction of Debt, Net
916.00
1,035.00
-
-
-
Net Financing Cash Flow
5,788.00
13,772.00
40,537.00
4,054.00
10,830.00
Net Change in Cash
1,859.00
2,822.00
386.00
7,931.00
6,596.00
Free Cash Flow
14,609.00
10,844.00
21,883.00
13,877.00
12,210.00
Other Sources
7,000.00
1.00
-
-
-
Change in Capital Stock
4,993.00
15,113.00
41,410.00
4,246.00
10,830.00

About MolMed

View Profile
Address
Via Olgettina, 58
Milan Milan 20132
Italy
Employees -
Website http://www.molmed.it
Updated 09/14/2018
Molecular Medicine SpA is a medical biotechnology company which focuses on the research, development and clinical validation of therapies to treat cancer. The company's approach is based on finding drugs that target the reduction of tumor mass in the acute stage, as well as on the provision of selective therapies to eliminate the residual disease. Its pipeline includes antitumor therapeutics in clinical and preclinical development: Zalmoxis (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression.